Celldex Therapeutics, Inc. — Director's Dealing 2012

Sep 13, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2012-09-12

Reporting Person: Davis Thomas Andrew (Sr. VP & CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-09-12	Incentive Stock Option	$5.69	A	115000	Acquired	2022-09-12	Common Stock (115000)	Direct

Footnotes

F1: 25% vest on September 12, 2013 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.